PyVST

Phase 1Biologic

NNational Institute of Neurological Disorders and Stroke (NINDS)

PyVST is one of 16 biologic programs targeting Progressive Multifocal Leukoencephalopathy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Progressive Multifocal LeukoencephalopathyActive, not recruiting

Progressive Multifocal LeukoencephalopathyPhase 1

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Progressive Multifocal Leukoencephalopathy

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

1 2

Videx

Bristol-Myers Squibb

Phase 2

1 3

Cytosar

Teva

Phase 2

1 4

Tembexa

Emergent BioSolutions

Phase 2

1 5

Hivid

CConrado Roberto Hoffmann Filho

Phase 2

1 6

Hycamtin

MMeitheal

Phase 2

1 7

Neupogen

EEastern Cooperative Oncology Group

Phase 2

1 8

Lariam

UUnited BioPharma

Phase 1

1 9

Tysabri

Biogen

Preclinical

1 10

Intron a

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Progressive Multifocal Leukoencephalopathy1 trial

A Pilot Study of Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-cells

Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 1·NCT02694783·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PyVST. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PyVST compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PyVST. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Neurological Disorders and Stroke (NINDS) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: NNational Institute of Neurological Disorders and Stroke (NINDS)

PyVST

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Progressive Multifocal Leukoencephalopathy1 trial

References

Drug Info

Quick Facts

Related News